HCM — HUTCHMED (China) Share Price
Last trade - 00:00- £1.87bn
- £1.31bn
- $630.20m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 14.28 | ||
| PEG Ratio (f) | 0.29 | ||
| EPS Growth (f) | 96.52% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.27 | ||
| Price to Tang. Book | 3.27 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.94 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5.4% | ||
| Return on Equity | 5.06% | ||
| Operating Margin | -7.7% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 227.98 | 356.13 | 426.41 | 838 | 630.2 | 705.25 | 867.02 | 25.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -60.87 | +368.03 | -39.73 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Directors
- Simon To CHM (68)
- Christian Hogg CEO (55)
- Chig Fung Cheng CFO (54)
- Mark Lee SVF (43)
- May Wang SVP (57)
- Zhenping Wu SVP (61)
- Weiguo Su CSO (63)
- Edith Shih SEC (69)
- Dan Eldar NED (67)
- Paul Carter NID (60)
- Karen Ferrante NID (63)
- Graeme Jack NID (71)
- Shu Kam Mok NID (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 18th, 2000
- Public Since
- May 19th, 2006
- No. of Employees
- 1,811
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 871,601,095
- Address
- 48Th Floor, Cheung Kong Center
- Web
- https://www.hutch-med.com/
- Phone
- +852 21281188
- Contact
- David Ng
- Auditors
- PricewaterhouseCoopers
Latest News for HCM
Upcoming Events for HCM
HUTCHMED (China) Ltd Annual Shareholders Meeting
HUTCHMED (China) Ltd Annual Shareholders Meeting
HUTCHMED (China) Ltd at Bank of America Global Healthcare Conference
HUTCHMED (China) Ltd at CICC Healthcare Forum
HUTCHMED (China) Ltd at CITIC CLSA Japan Forum
HUTCHMED (China) Ltd at JPMorgan Global China Summit
HUTCHMED (China) Ltd at Goldman Sachs Global Healthcare Conference
Half Year 2025 HUTCHMED (China) Ltd Earnings Release
Similar to HCM
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
BSF Enterprise
London Stock Exchange
FAQ
As of Today at 21:10 UTC, shares in HUTCHMED (China) are trading at 212.00p. This share price information is delayed by 15 minutes.
Shares in HUTCHMED (China) last closed at 212.00p and the price had moved by -21.48% over the past 365 days. In terms of relative price strength the HUTCHMED (China) share price has underperformed the FTSE All Share Index by -24.57% over the past year.
The overall consensus recommendation for HUTCHMED (China) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreHUTCHMED (China) does not currently pay a dividend.
HUTCHMED (China) does not currently pay a dividend.
HUTCHMED (China) does not currently pay a dividend.
To buy shares in HUTCHMED (China) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 212.00p, shares in HUTCHMED (China) had a market capitalisation of £1.87bn.
Here are the trading details for HUTCHMED (China):
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: HCM
Based on an overall assessment of its quality, value and momentum HUTCHMED (China) is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in HUTCHMED (China) is 371.60p. That is 75.28% above the last closing price of 212.00p.
Analysts covering HUTCHMED (China) currently have a consensus Earnings Per Share (EPS) forecast of $0.22 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HUTCHMED (China). Over the past six months, its share price has underperformed the FTSE All Share Index by -30.96%.
As of the last closing price of 212.00p, shares in HUTCHMED (China) were trading -18.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The HUTCHMED (China) PE ratio based on its reported earnings over the past 12 months is 14.28. The shares last closed at 212.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
HUTCHMED (China)'s management team is headed by:
- Simon To - CHM
- Christian Hogg - CEO
- Chig Fung Cheng - CFO
- Mark Lee - SVF
- May Wang - SVP
- Zhenping Wu - SVP
- Weiguo Su - CSO
- Edith Shih - SEC
- Dan Eldar - NED
- Paul Carter - NID
- Karen Ferrante - NID
- Graeme Jack - NID
- Shu Kam Mok - NID